Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income from Continuing Operations (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Income from Continuing Operations for 4 consecutive years, with 21335000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 67.53% to 21335000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 107303000.0, a 47.57% increase, with the full-year FY2025 number at 107322000.0, down 12.44% from a year prior.
  • Income from Continuing Operations was 21335000.0 for Q4 2025 at Day One Biopharmaceuticals, down from 19692000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 35840000.0 in Q3 2024 to a low of 112397000.0 in Q2 2024.
  • A 4-year average of 40188250.0 and a median of 38943500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 177.66% in 2024, then crashed 154.94% in 2025.
  • Day One Biopharmaceuticals' Income from Continuing Operations stood at 40083000.0 in 2022, then tumbled by 35.95% to 54493000.0 in 2023, then decreased by 20.58% to 65710000.0 in 2024, then skyrocketed by 67.53% to 21335000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Income from Continuing Operations are 21335000.0 (Q4 2025), 19692000.0 (Q3 2025), and 30303000.0 (Q2 2025).